Human Secretome Treatment for Psoriasis Patients: Literature Review

Abstract

Psoriasis is a chronic, immune-mediated inflammatory skin disease with systemic implications, including strong associations with metabolic disorders such as type 2 diabetes. Despite numerous treatment modalities—from topical agents to biologics—many patients experience suboptimal outcomes, adverse effects, or disease relapse. In recent years, the human secretome, particularly that derived from mesenchymal stromal cells (MSCs) and dental pulp stem cells (DPSCs), has gained increasing attention as a novel therapeutic avenue. The secretome encompasses a complex array of bioactive molecules, including cytokines, growth factors, extracellular vesicles, and microRNAs, which exhibit potent immunomodulatory, anti-inflammatory, and regenerative properties. This literature review aims to synthesize current evidence on the composition, mechanisms, and therapeutic potential of the human secretome in the context of psoriasis. We also explore its dual role in addressing both cutaneous symptoms and systemic comorbidities. By critically evaluating preclinical and early clinical studies, this review highlights the promise and challenges of secretome-based therapies, and outlines future directions for their clinical translation in dermatology. The findings support the growing interest in cell-free regenerative medicine as a safer, more targeted alternative to conventional psoriasis treatments.